A study of an injectable treatment for moderate-to-severe eczema
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new injectable medicine (nemolizumab) for people with moderate-to-severe eczema that hasn't been helped enough by topical treatments. It aims to reduce itching and skin symptoms. The trial will compare the drug to a placebo in Chinese participants.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older and have had eczema for at least 2 years.
- Your eczema is moderate to severe, covering at least 10% of your body surface.
- You have significant itching, rated at least 4 on a 0–10 scale.
- Topical treatments (like corticosteroid creams) have not worked well enough, or you have had to use strong ones for a long time.
- You are willing to apply allowed topical treatments (like steroid creams) during the study.
- If you are a woman who could become pregnant, you must agree to use approved birth control during the study and for 12 weeks after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well nemolizumab works in everyday practice for people with moderate-to-severe atopic dermatitis (eczema). It helps researchers understand the real-world benefits and safety of this treatment.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This study tests a new medication (IBI3033) for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. The goal is to see if it's safe and effective in reducing symptoms like itching and rash.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
This study tests an oral medication (EC-18) for moderate to severe atopic dermatitis (eczema) to see if it can improve symptoms like itching and skin rash. It may be an option for people whose eczema is not controlled by topical treatments.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.